An interventional study of Probiotic and Prebiotic in Obesity and Overweight, Obesity, Morbid and Metabolic Syndrome, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Obesity, Morbid with a site in Spain — 11 open to participants now, 14 under way, 1 of them phase 3. Obesity, Morbid · Spain.
Among the 38 studies in Obesity, Morbid with a site in Spain, this one is the 3rd largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 22 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 33rd registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →11 of the 38 studies in Obesity, Morbid with a site in Spain are open now. Recruiting first, the newest first:
Hospitales Universitarios Virgen del Rocío · Sites in Spain
Ages 18–74
Regeneron Pharmaceuticals · Sites in Spain, Germany, Turkey
Ages 2+
University of Alicante · Sites in Spain
Ages 18–70
Instituto de Investigacion Sanitaria La Fe · Sites in Spain
Ages 18–65
Corporacion Parc Tauli · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 230 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 68 across the 25 interventional studies, 145 across the 13 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 38 have an industry lead sponsor. The 10 most frequent:
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental has 1 study filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
2 of the studies in Obesity, Morbid with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220772Phase 3Regeneron PharmaceuticalsA Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | 2027-06-18 |
| NCT06226194Institut de Recerca Biomèdica de LleidaGenetic Susceptibility to Predict Weight Loss After Bariatric Surgery | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Obesity, Morbid with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obesity is one of the most severe and prevalent non-communicable diseases worldwide, affecting an estimated one-third of the population in Spain. It is a multifactorial disease that, in extreme cases such as morbid obesity, can become highly disabling and is associated with significant morbidity and mortality. This is because it serves as a risk factor for numerous chronic diseases, including metabolic conditions (type 2 diabetes mellitus), cardiovascular diseases (hypertension, atherosclerosis, etc.), and even cancer.
The exact etiopathogenic mechanisms are not fully understood, but subclinical inflammation is considered to form the basis of the metabolic (diabetes) and cardiovascular (endothelial dysfunction, dyslipidemia, etc.) disturbances that almost invariably accompany obesity. Additionally, alterations in the composition of the gut microbiota, or dysbiosis, are now recognized as playing a key role in the pathogenesis of obesity. This makes the gut microbiota a highly attractive therapeutic target for both the prevention and treatment of obesity, including less severe forms and morbid obesity.
In this context, the use of probiotics or extracts with prebiotic properties represents a particularly interesting strategy against obesity, offering a combination of efficacy and safety for treating these patients. Consequently, the general objective is proposed to evaluate the impact of dietary interventions aimed at modulating dysbiosis through the administration of a probiotic (Lactobacillus fermentum CECT5716), a standardized olive leaf extract with prebiotic properties, or a synbiotic (a combination of the olive leaf extract and L. fermentum CECT5716) on the clinical response of patients with moderate or morbid obesity. This will include determining its relationship with the immuno-metabolic system and the characteristic cardiovascular complications of obesity.
Furthermore, the evaluation of these treatments in experimental models of obesity, including morbid obesity requiring surgery, is also proposed. These models will include trials involving fecal material transfer into germ-free mice. These results will add significant value to the project by advancing our understanding of the underlying mechanisms of the disease. This will aid in the establishment of new diagnostic, prognostic, and therapeutic biomarkers, which are of great interest in reducing the incidence and prevalence of this current obesity epidemic.
The estimated duration for completing the project is 12 months, with its conclusion anticipated by March 2024.
Obesity: The Epidemic of the 21st Century and a Public Health Concern. Obesity is one of the most severe and prevalent non-communicable diseases of the 21st century, representing a global public health problem that affects all age groups. In Spain, it is estimated that over 39% of adults (aged 25-60) are overweight and 20% are obese, with Andalusia being one of the regions with the highest rates, which continue to rise. Obesity is a multifactorial, recurrent, and progressive disease associated with significant physical and psychological complications, as well as considerable morbidity and mortality. It is a key risk factor for numerous chronic conditions, including metabolic syndrome (type 2 diabetes mellitus, hypertension, dyslipidemia) and the associated elevated risk of cardiovascular diseases.
Moreover, obesity can increase the risk of other diseases, including digestive, respiratory, and joint disorders, as well as various types of cancer (esophagus, colon, pancreas, prostate, and breast). Although the pathogenic mechanisms underlying obesity are not fully elucidated, it is understood that obesity is linked to a state of chronic low-grade systemic inflammation. Dysregulated adipose tissue functionality in obese individuals leads to elevated free fatty acid levels and increased production of inflammatory cytokines, establishing a vicious cycle that promotes the hypertrophy and hyperplasia of adipocytes, hallmarks of obesity.
The excessive production of these mediators and their release into the bloodstream have a profound impact on other organs and systems, contributing to the metabolic (e.g., diabetes) and cardiovascular (e.g., endothelial dysfunction, atherosclerosis) alterations that almost invariably accompany obesity. Consequently, obesity is associated with reduced quality of life and has a significant negative socioeconomic impact. It is also a determinant of several "intermediate risk factors," leading to increased mortality and reduced life expectancy.
The treatment of obesity involves lifestyle and dietary changes, often supplemented by pharmacological therapy, including appetite suppressants and fat absorption inhibitors. However, these strategies may be insufficient, and for severe obesity (BMI >35) or morbid obesity (BMI >40), surgical intervention is often necessary. Bariatric surgery, despite its effectiveness in reducing metabolic and cardiovascular comorbidities and improving survival and quality of life, involves significant complications due to patient characteristics and high costs. Moreover, over the last 30 years, there has been a marked increase in the prevalence of morbid obesity and, consequently, a greater demand for bariatric surgery.
While surgery reduces comorbidities and enhances patient outcomes, its effects on the gut microbiota remain suboptimal. As such, specific dietary interventions before and/or after surgery are needed to improve microbial gene richness and ensure long-term metabolic health.
The Gut Microbiome as a Modifiable Factor in Obesity. Numerous studies have highlighted the critical role of the gut microbiome in the development and maintenance of obesity and its associated conditions. Research shows that the microbiome composition in lean individuals differs significantly from that in obese individuals, a condition known as dysbiosis. Obese individuals exhibit an increased Firmicutes/Bacteroidetes ratio, reduced microbial diversity, and enhanced energy extraction efficiency from food.
Dysbiosis is also associated with increased intestinal permeability, allowing bacterial components such as lipopolysaccharides (LPS) to enter systemic circulation, which promotes endotoxemia and exacerbates inflammation. This altered microbial composition is linked to increased production of short-chain fatty acids (SCFAs), particularly propionate, which may contribute to lipogenesis and gluconeogenesis.
Severe dysbiosis is observed in morbidly obese patients, characterized by drastic reductions in microbial richness, intensified systemic inflammation, and metabolic disturbances. Although bariatric surgery improves weight, metabolic markers, and microbial diversity, it does not restore microbiota richness to levels observed in lean individuals. Therefore, dietary interventions targeting microbial restoration are critical for post-surgical recovery and long-term health.
Modulation of the Microbiome in Obesity: Probiotics and Prebiotics. The selective modulation of the gut microbiome using probiotics and prebiotics has emerged as a promising therapy for obesity. Probiotics, defined as live microorganisms that confer health benefits when administered in adequate amounts, offer several advantages, including strengthening the intestinal barrier, immunomodulation, and restoring dysbiosis. Commonly used probiotics in obesity management include strains from the Lactobacillus and Bifidobacterium genera.
Studies in both animal models and humans have demonstrated that specific strains can reduce body weight, fat accumulation, lipid profiles, and inflammatory markers. However, the overall efficacy in humans has been modest, necessitating further research to identify optimal strains, dosages, and treatment durations.
Lactobacillus fermentum CECT5716 has shown immunomodulatory properties in experimental models of colitis and hypertension. Preliminary unpublished studies suggest that it can reduce weight gain and systemic inflammation in obesity models, likely by improving dysbiosis and intestinal barrier function.
Prebiotics, non-digestible dietary components that selectively stimulate beneficial gut bacteria, are also effective in obesity management. Phenolic compounds, such as oleuropein from olive leaves, have shown significant prebiotic potential, reducing fat deposition, improving lipid and glucose profiles, and mitigating inflammation and vascular dysfunction in animal studies.
The current project aims to evaluate the effects of dietary supplementation with L. fermentum CECT5716 or a standardized olive leaf extract, alone or in combination, on clinical outcomes in patients with moderate and morbid obesity. Specifically, it will assess their impact on dysbiosis, metabolic and cardiovascular health, and post-surgical recovery in morbidly obese patients. The intervention's effectiveness will be correlated with adherence to a Mediterranean diet. By integrating microbiomic and metabolomic analyses, the study seeks to establish a personalized treatment framework for obesity.
H1: L. fermentum CECT5716 and/or olive leaf extract supplementation reduces inflammation, metabolic disturbances, and cardiovascular complications in obesity.
H2: These interventions restore dysbiotic gut microbiota composition and function.
H3: Supplementation improves post-operative outcomes in morbidly obese patients.
H4: Combining probiotic and prebiotic interventions provides synergistic benefits, maximizing efficacy.
This project offers a comprehensive approach to addressing obesity through microbiome modulation, paving the way for innovative, personalized therapeutic strategies.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
This study's planned enrollment of 230 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo treated with 500 mg/capsule/day of maltodextrin
Dietary Supplement: Probiotic · Dietary Supplement: Prebiotic · Dietary Supplement: Synbiotic
capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716
Dietary Supplement: Prebiotic · Dietary Supplement: Synbiotic
500 mg/capsule/day of olive leaf extract, containing 35% oleuropein, an amount comparable to what could be consumed through daily intake of extra virgin olive oil.
Dietary Supplement: Probiotic · Dietary Supplement: Synbiotic
A combination of prebiotic and probiotic at the same doses.
Dietary Supplement: Probiotic · Dietary Supplement: Prebiotic
Treatment with capsules with 10\^9 CFU/ day of Limosilactobacillus fermentum CECT5716 during 6 months
Treatment with capsules 500 mg/capsule/day of olive leaf extract, containing 35% oleuropein during 6 months
A pill with a combination of prebiotic and probiotic at the same doses during 6 months
Evaluation of the composition of the intestinal microbiome using metagenomic analysis
Microbial DNA will be isolated from the intestinal contents (feces) of different groups at various time points (T0 and T6). Taxonomic group identification will be performed through metagenomic sequencing using the Nextera XT Library Preparation Kit (Illumina). Sequencing will be conducted on a NovaSeq-6000 platform. To analyze the microbiota taxonomy, the RAST platform will be used to classify reads into different amplicon sequence variants (ASVs). A dynamic threshold will be applied to filter out false or incorrect ASVs, eliminating those contributing less than 0.1% of the total sequence count. The ASVs table will then be normalized per sample using subsampling (or rarefaction) to a minimum read count. QIIME wrapper scripts (v1.9.1) will be employed to classify reads into taxonomic units and to identify taxa with differential abundance between groups.
Time frame: From enrollment (T0) to the end of treatment (6 months(T6))
Evaluation of the treatment using integrated data analysis
The data obtained from the different determinations conducted will be automated for integrated analysis. Variables will be normalized, and qualitative variables will be categorized. Integrated bioinformatics analysis will compare and functionally correlate nutritional data, omics data (microbiomics, metabolomics, and immunological profiles) with clinical phenotypes (obese and morbidly obese patients) and treatments (probiotic, prebiotic, and synbiotic). This analysis will be based on Bayesian methods, which provide a statistical framework enabling the probabilistic integration of information across multiple analysis steps. All data will be analyzed using R and GraphPad Prism (version 8.4.1). This approach will allow the identification of relationships between microbiota impact and the administered treatments, as well as determine which treatment demonstrated the highest efficacy.
Time frame: From enrollment (T0) to the end of treatment (6 months(T6))
Evaluation of serological biochemical profile
In blood samples collected at different points of the study (baseline and endpoint), the following parameters will be assessed using an autoanalyzer (Beckman Coulter AU5800): serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and γ-glutamyl transpeptidase (GGT), total bilirubin, creatinine, uric acid, and lipid profile, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and low-density lipoprotein cholesterol (LDL). Serum leptin, IL-6, and TNF-α will be measured using the MILLIPLEX MAG Human Adipokine Magnetic Bead Panel (Millipore). Serum adiponectin, lipopolysaccharide-binding protein (LBP), and insulin will be quantified using ELISA kits. All variables will be quantified in IU/L.
Time frame: From enrollment to the end of treatment (6 months)
Determination of the treatment impact on the metabolome profile
Metabolomic studies from serum samples at two different points (initial and final point) will be performed usign HPLC-GS-GC (min and m/z).
Time frame: From enrollment (T0) to the end of treatment (6 months(T6))
Plan to share: No
Ran from Feb 2024 to primary completion in Mar 2025, 13 months.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's 13 months is below that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental